Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.30.
A number of equities research analysts have recently weighed in on CGTX shares. HC Wainwright lifted their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Chardan Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Cognition Therapeutics in a research note on Thursday, December 19th.
View Our Latest Stock Analysis on Cognition Therapeutics
Cognition Therapeutics Stock Performance
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV lifted its holdings in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the last quarter. Sigma Planning Corp lifted its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Cognition Therapeutics during the fourth quarter worth approximately $26,000. Finally, Virtu Financial LLC acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $27,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.
Cognition Therapeutics Company Profile
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Featured Stories
- Five stocks we like better than Cognition Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How to Invest in the FAANG Stocks
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How Technical Indicators Can Help You Find Oversold Stocks
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.